ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2257

MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis

Walter P Maksymowych1, Mikkel Østergaard2, Xenofon Baraliakos3, Pedro Machado4, Susanne J. Pedersen5, Ulrich Weber6, Iris Eshed7, Manouk de Hooge8, Joachim Sieper9, Denis Poddubnyy10, Martin Rudwaleit11, Désirée van der Heijde12, Robert Landewé13 and Robert G Lambert14, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 3Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 4University College London, London, United Kingdom, 5Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 6Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, 7Sheba Medical Center, Tel Aviv, Israel, 8Ghent University Hospital, Luxembourg, Luxembourg, 9Charité - Universitätsmedizin, Berlin, Berlin, Germany, 10Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 11University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 12Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 13Amsterdam University Medical Center, Meerssen, Netherlands, 14University of Alberta, Edmonton, AB, Canada

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), classification criteria, Magnetic resonance imaging (MRI), spondyloarthritis, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: There is limited data as to the frequency of spinal lesions on MRI in patients without MRI or radiographic features typical of sacroiliac joint (SIJ) disease in axial spondyloarthritis (axSpA). This may inform to what degree spine MRI might enhance the diagnostic information provided by SIJ MRI alone. We aimed to assess the frequency of MRI lesions of the spine in the ASAS-Classification Cohort according to the presence of MRI SIJ lesions typical of axSpA and/or radiographic sacroiliitis according to the modified New York criteria (mNY+).

Methods: MRI spine lesions were recorded by 9 central readers in an eCRF that captures global assessment of the spine (“Is the MRI consistent with axSpA: yes/no”) (yes=MRIglobal spine+) and detailed anatomical-based scoring of each discovertebral unit plus lateral and posterior structures for bone marrow edema, fat lesions, erosion, and ankylosis, according to ASAS standardized definitions for spinal lesions. Independently, readers globally assessed SIJ scans for active and/or structural lesions typical of axSpA (MRIglobal SIJ+) . We compared the frequency of a positive MRIglobal spine+ and frequencies of different types of spinal lesions according to the presence/absence of axSpA on global evaluation of SIJ MRI scans by ≥5 of 9 readers (MRIglobal SIJ+) and according to the presence/absence of mNY+ radiographic sacroiliitis using Fisher’s exact test. Analysis was also stratified by rheumatologist clinical diagnosis.

Results: Among 51 cases with SIJ as well as spine MRI scans and radiographs of the SIJ,19 (37.3%) had a positive MRIglobal SIJ+ scan, and 12 (23.5%) and 7 (13.7%) had a positive MRIglobal spine+ scan according to ≥2 and ≥5 reader agreement, respectively. A positive MRIglobal spine+ scan occurred significantly more frequently in the presence of a positive MRIglobal SIJ+ scan (Table 1) and the presence of radiographic sacroiliitis but was also recorded in 4 of 32(12.5%) (≥2 readers) and 1 of 32(3.4%) (≥5 readers) cases that were negative for a MRIglobal SIJ- scan and x-ray negative (Table 2), all 4 cases being diagnosed with axSpA. Moreover, vertebral corner BME lesions, but not spinal structural lesions, were significantly more frequent in cases that were negative for a MRIglobal SIJ- scan but had been clinically diagnosed as axSpA versus non-axSpA (Table 3).

Conclusion: Spinal lesions on MRI indicative of axSpA per majority central read occurred in about 3% of patients without positive imaging in the SIJ on either MRI or radiography. Frequency of spinal vertebral corner BME lesions was significantly higher in cases with negative SIJ imaging on either MRI or radiography but clinically diagnosed with axSpA.

Supporting image 1

Table 1. Frequency of Spinal MRI lesions According to an MRI SIJ scan Positive for AxSpA

Supporting image 2

Table 2. Frequency of Spinal MRI lesions According to an MRI SIJ scan Positive for AxSpA and/or Presence/Absence of Radiographic Sacroiliitis (mNY+)

Supporting image 3

Table 3. Frequency of Spinal MRI lesions in Cases with Negative MRI SIJ scan for AxSpA according to Presence/Absence of Clinical Diagnosis of axSpA


Disclosures: W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited; M. Østergaard, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Janssen, Gilead, Novartis, Pfizer, UCB; X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi; P. Machado, AbbVie/Abbott, Eli Lilly, UCB, Novartis, Orphazyme, Galapagos; S. Pedersen, Novartis, AbbVie/Abbott, UCB, Pfizer, Merck/MSD; U. Weber, None; I. Eshed, None; M. de Hooge, None; J. Sieper, AbbVie/Abbott, Novartis, Eli Lilly, Merck/MSD, UCB, Janssen, Pfizer, Roche; D. Poddubnyy, AbbVie, Biocad, Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline, MSD, Moonlake, Novartis, Pfizer, Samsung-Bioepis, UCB; M. Rudwaleit, AbbVie, Bristol-Myers Squibb (BMS), Boehringer-Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma; D. van der Heijde, AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Novartis, Pfizer, UCB, Imaging Rheumatology bv, Lilly; R. Landewé, Abbott, Amgen, AstraZeneca, BMS, GSK, Novartis, Merck, Pfizer, Schering-Plough, UCB Pharma; R. Lambert, Calyx, CARE Arthritis, Image Analysis Group.

To cite this abstract in AMA style:

Maksymowych W, Østergaard M, Baraliakos X, Machado P, Pedersen S, Weber U, Eshed I, de Hooge M, Sieper J, Poddubnyy D, Rudwaleit M, van der Heijde D, Landewé R, Lambert R. MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/mri-spinal-lesions-in-patients-without-mri-or-radiographic-lesions-in-the-sacroiliac-joints-typical-of-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mri-spinal-lesions-in-patients-without-mri-or-radiographic-lesions-in-the-sacroiliac-joints-typical-of-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology